Joinn Biologics Completes Acquisiton of Lonza’s Guangzhou Facility

• Joinn Biologics has acquired Lonza’s 183,000-square-foot manufacturing plant in Guangzhou, China.

• The facility enhances Joinn’s biologics CDMO capabilities across the Asia-Pacific region.

Joinn Biologics, a San Francisco-based CDMO, has completed the acquisition of Lonza’s Guangzhou manufacturing facility, strengthening its foothold in China’s Greater Bay Area. The plant, spanning 183,000 square feet, is equipped with cutting-edge modular and digital production workshops, enabling small-batch and large-scale biologics manufacturing.

The facility includes two 1,000-liter and two 2,000-liter disposable liquid production lines, preparation filling lines for various dosage forms, and quality control labs. It offers end-to-end services such as cell line production, process development, and formulation production, supporting Joinn’s goal to serve the Asia-Pacific market effectively.

The financial details of the transaction were not disclosed, but a Lonza spokesperson confirmed the sale. The site was initially acquired by Lonza from GE HealthCare in 2018 and opened in 2021 before being shuttered last year as part of Lonza’s cost-reduction strategy. Despite the closure, Lonza continues operations in China through facilities in Nansha and Suzhou.

Founded in 2018, Joinn Biologics operates under Joinn Laboratories, a 30-year-old contract research organisation. The company employs over 500 staff across its U.S. and China facilities, which feature a range of production lines for biologics. The acquisition aligns with Joinn’s ambition to establish a strategic presence in the Greater Bay Area and expand its contract manufacturing capabilities globally.